SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is experiencing a surge due to recent news signaling a significant initiative to lower mortgage rates, which the community widely anticipates will ignite a housing market comeback. Investors are actively discussing a potential short squeeze and rapid price appreciation, believing that increased transaction activity from more accessible mortgage rates will directly benefit Opendoor's business model.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following a strong earnings report that showcased significant revenue growth and an ambitious outlook for its AI data center capacity. The community is actively debating a potential short squeeze, fueled by high trading volume and recent analyst upgrades pointing to considerable upside. Investors are closely monitoring the company's strategic expansion within the booming AI infrastructure sector and anticipating further hyperscaler contract announcements.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending due to intense investor frustration over its prolonged underperformance, despite the company's strong fundamentals, low valuation, and active share buyback program. The community remains sharply divided, with many expressing exasperation at management's perceived inability to unlock value, while others view the current price as a generational buying opportunity in the digital payments sector.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending sharply higher after Meta Platforms announced a major agreement to develop a 1.2 GW nuclear energy campus for its AI data centers. The community is actively discussing potential short squeezes and anticipated analyst upgrades, though some express skepticism regarding Oklo's current lack of revenue and long-term project timelines. This deal highlights the growing demand for stable, large-scale power solutions for AI infrastructure, positioning advanced nuclear companies in a critical role.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is trending with significant community engagement, driven by its multi-chain presence across Solana, Cronos, and Base utilizing Layerzero technology. The community actively promotes its deflationary burn mechanism and organic growth, rallying behind the ambitious mission to become the number one memecoin by surpassing others like Dogecoin. This passionate discussion highlights $CAW's unique characteristics and potential in the evolving crypto landscape.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending due to its prominent presence at CES 2026, showcasing advanced agentic and conversational AI solutions, including a new partnership with TomTom for multi-agent voice navigation. The community is actively discussing the company's significant short interest and robust industry integrations, believing its unique AI architecture and expanding real-world applications position it for substantial future growth.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is facing increased competitive pressure as Novo Nordisk's oral GLP-1 weight loss pill is now available on rival platforms but not through Hims, sparking community debate over its market position. While a recent analyst downgrade citing margin pressure has weighed on the stock, many investors are highlighting its oversold status and high short interest, anticipating a potential rebound driven by its diversified telehealth offerings.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase Global is trending due to recent analyst upgrades from Bank of America and Goldman Sachs, which highlighted its strategic shift to become an "everything exchange" encompassing traditional assets and prediction markets. The community is actively discussing the potential for significant upside as the company solidifies its position as a key player in the evolving crypto and broader financial ecosystem, especially with Bitcoin showing renewed strength.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is a major talking point after MSCI decided against excluding digital-asset firms from its indexes, providing immediate relief from a key overhang. Despite this positive catalyst, community sentiment remains deeply divided, with bulls anticipating a significant reversal or "gamma squeeze" while bears aggressively point to ongoing share dilution and the prevailing "crypto winter" narrative as critical headwinds. Traders are closely watching options expiration and "max pain" levels, fueling intense debate over the stock's direction.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is experiencing significant bullish momentum, largely driven by a recent Bank of America upgrade and widespread community dismissal of a prior bearish analyst report. Investors are actively discussing expectations for imminent news regarding the BlueBird 6 satellite's unfurling and an accelerated deployment schedule, reinforcing conviction in the company's patented direct-to-device cellular broadband technology and its long-term potential in space communications.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$COGT  
 
Cogent Biosciences submits NDA for bezuclastinib in NonAdvSM 
 
Cogent Biosciences submitted its New Drug Application to the U.S. Food and Drug Administration for bezuclastinib in NonAdvanced Systemic Mastocytosis. The submission is based on positive clinical data from the SUMMIT pivotal trial and follows the Breakthrough Therapy Designation for bezuclastinib in patients with SSM and patients with NonAdvSM who have received prior avapritinib. As reported first in July, and more recently at the ASH annual meeting, the SUMMIT trial of bezuclastinib in patients with NonAdvSM achieved statistical significance across all primary and key secondary endpoints.  
 
Bezuclastinib demonstrated clear clinical benefit across all symptom domains, including significant improvements across 11 individual patient reported symptoms as well as the most severe symptom at baseline. Reductions in objective measures of disease, including serum tryptase, correlated with improvements in symptom severity, representing the first time this relationship has been demonstrated in patients with NonAdvSM. Updated data from the SUMMIT trial through 48 weeks showcased a clear and continued deepening of symptomatic improvement over time, supporting the potential for sustained clinical benefit with longer duration of therapy. Across the SUMMIT trial, bezuclastinib de 
...

StockTwits Web

Cogent Biosciences Inc

  
 
Cogent Biosciences submits NDA for bezuclastinib in NonAdvSM 
 
Cogent Biosciences submitted its New Drug Application to the U.S. Food and Drug Administration for bezuclastinib in NonAdvanced Systemic Mastocytosis. The submission is based on positive clinical data from the SUMMIT pivotal trial and follows the Breakthrough Therapy Designation for bezuclastinib in patients with SSM and patients with NonAdvSM who have received prior avapritinib. As reported first in July, and more recently at the ASH annual meeting, the SUMMIT trial of bezuclastinib in patients with NonAdvSM achieved statistical significance across all primary and key secondary endpoints.  
 
Bezuclastinib demonstrated clear clinical benefit across all symptom domains, including significant improvements across 11 individual patient reported symptoms as well as the most severe symptom at baseline. Reductions in objective measures of disease, including serum tryptase, correlated with improvements in symptom severity, representing the first time this relationship has been demonstrated in patients with NonAdvSM. Updated data from the SUMMIT trial through 48 weeks showcased a clear and continued deepening of symptomatic improvement over time, supporting the potential for sustained clinical benefit with longer duration of therapy. Across the SUMMIT trial, bezuclastinib de 
...